Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2017

Dec 20, 2017

32134_dirs_2017-12-19_3b2efa07-c01b-4cd0-b659-ce4548a55bda.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-12-15

Reporting Person: Nicholson John (SVP & Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-12-15 Common Stock A 26000 $0.00 Acquired 272536 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-15 Stock Option $56.90 A 65000 Acquired 2025-12-14 Common Stock (65000) Direct

Footnotes

F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.

F2: This stock option vests over four years in equal monthly installments based on continued service.